Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients

Rin Ogiya, Naoki Niikura, Nobue Kumaki, Giampaolo Bianchini, Shigehisa Kitano, Takayuki Iwamoto, Naoki Hayashi, Kozue Yokoyama, Risa Oshitanai, Mayako Terao, Toru Morioka, Banri Tsuda, Takuho Okamura, Yuki Saito, Yasuhiro Suzuki, Yutaka Tokuda

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The presence of tumor-infiltrating lymphocytes (TILs) is associated with favorable long-term outcome in breast cancer. However, little is known about changes in TILs during metastatic progression. To confirm our hypothesis that malignant tumors escape from the host immune system during metastasis, we evaluated the percentage of TILs in paired samples of primary and metastatic breast tumors. We retrospectively identified 25 patients with human epidermal growth factor receptor-2 (HER2+, n = 14) and triple negative (TN, n = 11) early breast cancer diagnosed between 1990 and 2009 at Tokai University Hospital (Isehara, Japan) and who subsequently experienced regional or distant recurrence confirmed by tumor biopsy/resection. Hematoxylin–eosin-stained slides of these paired samples were evaluated for stromal TILs. Immunohistochemical staining was carried out using primary antibodies against CD4, CD8, Foxp3, programmed cell death ligand 1 (PD-L1), PD-L2, and HLA class I for characterizing the TILs and breast tumors. The percentage of TILs in the primary tumors was significantly higher (average 34.6%) than that in metastatic tumors (average 15.7%) (paired t-test, P = 0.004) and that of CD8+ and CD4+ T cells significantly decreased from primary to metastatic tumors (paired t-test, P = 0.008 and P = 0.026, respectively). The PD-L1, PD-L2, and HLA class I antibody expression changed from positive to negative and vice versa from the primary to the metastatic tumors. Tumors at first metastatic recurrence in HER2+ and TN breast cancers have a lower percentage of TILs and CD8+ and CD4+ T cells compared to primary tumors, which indicates that immune escape plays a role in tumor progression.

Original languageEnglish
Pages (from-to)1730-1735
Number of pages6
JournalCancer Science
Volume107
Issue number12
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Tumor-Infiltrating Lymphocytes
Breast Neoplasms
Programmed Cell Death 1 Ligand 2 Protein
Neoplasms
Cell Death
Tumor Escape
T-Lymphocytes
Recurrence
Immunoglobulin Isotypes
Immune System
Japan
Staining and Labeling
Neoplasm Metastasis
Biopsy
Antibodies

Keywords

  • Immune microenvironment
  • immunohistochemistry
  • metastatic breast tumor
  • primary breast tumor
  • tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. / Ogiya, Rin; Niikura, Naoki; Kumaki, Nobue; Bianchini, Giampaolo; Kitano, Shigehisa; Iwamoto, Takayuki; Hayashi, Naoki; Yokoyama, Kozue; Oshitanai, Risa; Terao, Mayako; Morioka, Toru; Tsuda, Banri; Okamura, Takuho; Saito, Yuki; Suzuki, Yasuhiro; Tokuda, Yutaka.

In: Cancer Science, Vol. 107, No. 12, 01.12.2016, p. 1730-1735.

Research output: Contribution to journalArticle

Ogiya, R, Niikura, N, Kumaki, N, Bianchini, G, Kitano, S, Iwamoto, T, Hayashi, N, Yokoyama, K, Oshitanai, R, Terao, M, Morioka, T, Tsuda, B, Okamura, T, Saito, Y, Suzuki, Y & Tokuda, Y 2016, 'Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients', Cancer Science, vol. 107, no. 12, pp. 1730-1735. https://doi.org/10.1111/cas.13101
Ogiya, Rin ; Niikura, Naoki ; Kumaki, Nobue ; Bianchini, Giampaolo ; Kitano, Shigehisa ; Iwamoto, Takayuki ; Hayashi, Naoki ; Yokoyama, Kozue ; Oshitanai, Risa ; Terao, Mayako ; Morioka, Toru ; Tsuda, Banri ; Okamura, Takuho ; Saito, Yuki ; Suzuki, Yasuhiro ; Tokuda, Yutaka. / Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients. In: Cancer Science. 2016 ; Vol. 107, No. 12. pp. 1730-1735.
@article{5219e056ec8f45d7b9523a6acfe40315,
title = "Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients",
abstract = "The presence of tumor-infiltrating lymphocytes (TILs) is associated with favorable long-term outcome in breast cancer. However, little is known about changes in TILs during metastatic progression. To confirm our hypothesis that malignant tumors escape from the host immune system during metastasis, we evaluated the percentage of TILs in paired samples of primary and metastatic breast tumors. We retrospectively identified 25 patients with human epidermal growth factor receptor-2 (HER2+, n = 14) and triple negative (TN, n = 11) early breast cancer diagnosed between 1990 and 2009 at Tokai University Hospital (Isehara, Japan) and who subsequently experienced regional or distant recurrence confirmed by tumor biopsy/resection. Hematoxylin–eosin-stained slides of these paired samples were evaluated for stromal TILs. Immunohistochemical staining was carried out using primary antibodies against CD4, CD8, Foxp3, programmed cell death ligand 1 (PD-L1), PD-L2, and HLA class I for characterizing the TILs and breast tumors. The percentage of TILs in the primary tumors was significantly higher (average 34.6{\%}) than that in metastatic tumors (average 15.7{\%}) (paired t-test, P = 0.004) and that of CD8+ and CD4+ T cells significantly decreased from primary to metastatic tumors (paired t-test, P = 0.008 and P = 0.026, respectively). The PD-L1, PD-L2, and HLA class I antibody expression changed from positive to negative and vice versa from the primary to the metastatic tumors. Tumors at first metastatic recurrence in HER2+ and TN breast cancers have a lower percentage of TILs and CD8+ and CD4+ T cells compared to primary tumors, which indicates that immune escape plays a role in tumor progression.",
keywords = "Immune microenvironment, immunohistochemistry, metastatic breast tumor, primary breast tumor, tumor-infiltrating lymphocytes",
author = "Rin Ogiya and Naoki Niikura and Nobue Kumaki and Giampaolo Bianchini and Shigehisa Kitano and Takayuki Iwamoto and Naoki Hayashi and Kozue Yokoyama and Risa Oshitanai and Mayako Terao and Toru Morioka and Banri Tsuda and Takuho Okamura and Yuki Saito and Yasuhiro Suzuki and Yutaka Tokuda",
year = "2016",
month = "12",
day = "1",
doi = "10.1111/cas.13101",
language = "English",
volume = "107",
pages = "1730--1735",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "12",

}

TY - JOUR

T1 - Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients

AU - Ogiya, Rin

AU - Niikura, Naoki

AU - Kumaki, Nobue

AU - Bianchini, Giampaolo

AU - Kitano, Shigehisa

AU - Iwamoto, Takayuki

AU - Hayashi, Naoki

AU - Yokoyama, Kozue

AU - Oshitanai, Risa

AU - Terao, Mayako

AU - Morioka, Toru

AU - Tsuda, Banri

AU - Okamura, Takuho

AU - Saito, Yuki

AU - Suzuki, Yasuhiro

AU - Tokuda, Yutaka

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The presence of tumor-infiltrating lymphocytes (TILs) is associated with favorable long-term outcome in breast cancer. However, little is known about changes in TILs during metastatic progression. To confirm our hypothesis that malignant tumors escape from the host immune system during metastasis, we evaluated the percentage of TILs in paired samples of primary and metastatic breast tumors. We retrospectively identified 25 patients with human epidermal growth factor receptor-2 (HER2+, n = 14) and triple negative (TN, n = 11) early breast cancer diagnosed between 1990 and 2009 at Tokai University Hospital (Isehara, Japan) and who subsequently experienced regional or distant recurrence confirmed by tumor biopsy/resection. Hematoxylin–eosin-stained slides of these paired samples were evaluated for stromal TILs. Immunohistochemical staining was carried out using primary antibodies against CD4, CD8, Foxp3, programmed cell death ligand 1 (PD-L1), PD-L2, and HLA class I for characterizing the TILs and breast tumors. The percentage of TILs in the primary tumors was significantly higher (average 34.6%) than that in metastatic tumors (average 15.7%) (paired t-test, P = 0.004) and that of CD8+ and CD4+ T cells significantly decreased from primary to metastatic tumors (paired t-test, P = 0.008 and P = 0.026, respectively). The PD-L1, PD-L2, and HLA class I antibody expression changed from positive to negative and vice versa from the primary to the metastatic tumors. Tumors at first metastatic recurrence in HER2+ and TN breast cancers have a lower percentage of TILs and CD8+ and CD4+ T cells compared to primary tumors, which indicates that immune escape plays a role in tumor progression.

AB - The presence of tumor-infiltrating lymphocytes (TILs) is associated with favorable long-term outcome in breast cancer. However, little is known about changes in TILs during metastatic progression. To confirm our hypothesis that malignant tumors escape from the host immune system during metastasis, we evaluated the percentage of TILs in paired samples of primary and metastatic breast tumors. We retrospectively identified 25 patients with human epidermal growth factor receptor-2 (HER2+, n = 14) and triple negative (TN, n = 11) early breast cancer diagnosed between 1990 and 2009 at Tokai University Hospital (Isehara, Japan) and who subsequently experienced regional or distant recurrence confirmed by tumor biopsy/resection. Hematoxylin–eosin-stained slides of these paired samples were evaluated for stromal TILs. Immunohistochemical staining was carried out using primary antibodies against CD4, CD8, Foxp3, programmed cell death ligand 1 (PD-L1), PD-L2, and HLA class I for characterizing the TILs and breast tumors. The percentage of TILs in the primary tumors was significantly higher (average 34.6%) than that in metastatic tumors (average 15.7%) (paired t-test, P = 0.004) and that of CD8+ and CD4+ T cells significantly decreased from primary to metastatic tumors (paired t-test, P = 0.008 and P = 0.026, respectively). The PD-L1, PD-L2, and HLA class I antibody expression changed from positive to negative and vice versa from the primary to the metastatic tumors. Tumors at first metastatic recurrence in HER2+ and TN breast cancers have a lower percentage of TILs and CD8+ and CD4+ T cells compared to primary tumors, which indicates that immune escape plays a role in tumor progression.

KW - Immune microenvironment

KW - immunohistochemistry

KW - metastatic breast tumor

KW - primary breast tumor

KW - tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85007335629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007335629&partnerID=8YFLogxK

U2 - 10.1111/cas.13101

DO - 10.1111/cas.13101

M3 - Article

AN - SCOPUS:85007335629

VL - 107

SP - 1730

EP - 1735

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 12

ER -